Ascletis Pharma, Inc.

As of December 31, 2025, Ascletis Pharma, Inc. carries a market capitalization of 11.23B, placing it among publicly traded companies globally. Its enterprise value stands at 9.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Ascletis Pharma, Inc.'s next confirmed earnings release is scheduled for March 30, 2027.

As of December 31, 2025, Ascletis Pharma, Inc. has 986.09M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Ascletis Pharma, Inc. maintains a current ratio of 15.05, meaning it holds 15.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Ascletis Pharma, Inc.'s stock has declined approximately 40.12% over the past 52 weeks. The 50-day moving average sits at 8.85, while the 200-day moving average is 12.39.

As of December 31, 2025, Ascletis Pharma, Inc. holds 2.12B in cash and equivalents against 5.74M in total debt, resulting in a net debt position of -1.61B. Total book value stands at 2.15B, with working capital of 2.00B providing operational flexibility.